This is a Zepbound news story, published by CNBC, that relates primarily to Mounjaro news.
For more Zepbound news, you can click here:
more Zepbound newsFor more Mounjaro news, you can click here:
more Mounjaro newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from CNBC, you can click here:
more news from CNBCOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
quarter revenue. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest earnings news, year revenue outlook news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
quarter earningsCNBC
•
73% Informative
Shares of Eli Lilly jumped more than 9% in premarket trading Thursday .
The company posted second-quarter revenue of $11.30 billion , up 36% from the same period a year ago .
The results come almost one week after the Food and Drug Administration said all doses of Zepbound and Mounjaro are available in the U.S ..
VR Score
81
Informative language
86
Neutral language
19
Article tone
formal
Language
English
Language complexity
41
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links